Médicaments contre l'insuffisance cardiaque : agents inotropes

Positive inotropic agents enhance cardiac output by increasing sarcomere contractility through elevation of free cytosolic calcium levels. This boosts contraction force and cardiac output, improving myocardial function. By enhancing contractility, these drugs also improve renal perfusion and alleviate cardiac stress in heart failure patients.

Cardiac glycosides inhibit the Na+/K+-ATPase pump, raising intracellular sodium concentrations while blocking calcium extrusion. This increases intracellular calcium availability, enhancing myocardial contractility. Digoxin, derived from the Digitalis genus and used since 1785, remains a potent positive inotropic agent despite its narrow therapeutic window.

Cardiac glycoside effects depend critically on plasma concentration. Low levels enhance parasympathetic activity beneficially, while high concentrations cause calcium overload, mesenteric artery ischemia, and sinus rhythm disturbances. This concentration-dependent toxicity necessitates careful monitoring of serum electrolytes and patient response to minimize risks and prevent arrhythmias.

Potassium levels critically influence cardiac glycoside interactions; low potassium inhibits enzyme-inhibiting actions and increases cardiac automaticity, raising toxicity risk. Hypercalcemia increases digitalis-induced arrhythmia risk, while magnesium has protective effects. Careful serum electrolyte monitoring is essential to prevent arrhythmias and maintain therapeutic safety.

Common side effects of positive inotropic agents include gastrointestinal symptoms such as nausea and vomiting, and neurotoxic symptoms affecting the central nervous system. Electrolyte imbalances may trigger arrhythmias or toxicity. These adverse effects require careful patient monitoring and dose adjustment to maintain therapeutic benefit while minimizing harm.

Beyond cardiac glycosides, positive inotropic agents include beta-adrenoceptor agonists like dobutamine, phosphodiesterase III inhibitors such as milrinone, and steroid derivatives. These agents have different mechanisms of action and therapeutic effects. However, their use requires careful consideration due to potential adverse effects and narrow therapeutic windows.

Treatment for cardiac glycoside toxicity involves stopping the medication immediately. Severe arrhythmias may require active interventions such as atropine or temporary pacemaker for bradycardia, or potassium infusion for fast ventricular arrhythmias. Anti-digoxin immunotherapy serves as the specific antidote for severe digitalis toxicity.